Bcr-Abl
Bcr-Abl inhibitors are targeted therapies that inhibit the Bcr-Abl fusion protein, which is formed due to the Philadelphia chromosome translocation and is a driver of chronic myeloid leukemia (CML). This protein also influences angiogenesis, contributing to tumor progression. Bcr-Abl inhibitors are crucial in the treatment of CML and are being explored for their potential in inhibiting angiogenesis in various cancers. At CymitQuimica, we provide high-quality Bcr-Abl inhibitors to support your research in cancer biology, angiogenesis, and targeted therapy.
Products of "Bcr-Abl"
Sort by
GNF-5
CAS:GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.Formula:C20H17F3N4O3Purity:98% - 99.98%Color and Shape:SolidMolecular weight:418.37Pivanex
CAS:Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.Formula:C10H18O4Purity:≥98%Color and Shape:SolidMolecular weight:202.25AST 487
CAS:AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.Formula:C26H30F3N7O2Purity:98.17% - 99.56%Color and Shape:SolidMolecular weight:529.56Ref: TM-T4053
1mg37.00€2mg52.00€5mg79.00€10mg119.00€25mg187.00€50mg354.00€100mg528.00€500mg1,159.00€1mL*10mM (DMSO)92.00€Multi-kinase inhibitor 1
CAS:Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.Formula:C20H17F3N4O3Purity:99.34%Color and Shape:SolidMolecular weight:418.37Nilotinib
CAS:Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.Formula:C28H22F3N7OPurity:99.61% - 99.83%Color and Shape:Off-White SolidMolecular weight:529.52HG-7-85-01
CAS:HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.Formula:C31H31F3N6O2SPurity:98.08%Color and Shape:SolidMolecular weight:608.68Imatinib impurities3
CAS:Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.Formula:C24H20ClN5OPurity:97.05%Color and Shape:SolidMolecular weight:429.9Olverembatinib dimesylate
CAS:Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Formula:C29H27F3N6O·2CH4O3SPurity:100% - 99.81%Color and Shape:SolidMolecular weight:724.77Ref: TM-T2429
1mg39.00€2mg51.00€5mg84.00€10mg119.00€25mg229.00€50mg319.00€100mg474.00€1mL*10mM (DMSO)120.00€BCR-ABL-IN-7
CAS:BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.Formula:C19H16FN3O3SPurity:98.28%Color and Shape:SolidMolecular weight:385.41Bosutinib
CAS:Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Formula:C26H29Cl2N5O3Purity:98.98% - 99.9%Color and Shape:Yellowish-Orange Or Pink To Brownish Solid Solid PowderMolecular weight:530.45Nocodazole
CAS:Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Formula:C14H11N3O3SPurity:98% - 99.91%Color and Shape:Physical Description White Powder (Ntp 1992)Molecular weight:301.32Ref: TM-T2802
5mg37.00€10mg55.00€25mg99.00€50mg168.00€100mg283.00€200mg420.00€500mg682.00€1mL*10mM (DMSO)40.00€BCR-ABL-IN-10
BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).Formula:C24H22N4O5SColor and Shape:SolidMolecular weight:478.52GNF-2
CAS:GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.Formula:C18H13F3N4O2Purity:98.17% - ≥95%Color and Shape:SolidMolecular weight:374.32PD180970
CAS:PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.Formula:C21H15Cl2FN4OPurity:98.47%Color and Shape:SolidMolecular weight:429.27PF-06651481-00
CAS:PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.Formula:C26H29Cl2N5O3Purity:97.57%Color and Shape:SolidMolecular weight:530.45N-Desmethyl imatinib
CAS:N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.Formula:C28H29N7OPurity:98.60%Color and Shape:Off-White To Pale-Yellow SolidMolecular weight:479.58Ref: TM-T11641
1mg92.00€5mg170.00€10mg319.00€25mg540.00€50mg777.00€100mg1,074.00€1mL*10mM (DMSO)178.00€AKE-72
CAS:AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.Formula:C30H29F3N6OPurity:98.3%Color and Shape:SoildMolecular weight:546.59Radotinib
CAS:Radotinib (IY-5511), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notablyFormula:C27H21F3N8OPurity:99.13% - 99.97%Color and Shape:SolidMolecular weight:530.5LXH254
CAS:LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.Formula:C25H25F3N4O4Purity:98.3% - 99.92%Color and Shape:SolidMolecular weight:502.49Ref: TM-T11898
1mg52.00€5mg122.00€10mg185.00€25mg363.00€50mg567.00€100mg690.00€200mg948.00€500mg1,444.00€1mL*10mM (DMSO)135.00€AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Formula:C19H23N7O2Purity:99.83% - 99.98%Color and Shape:SolidMolecular weight:381.43Ref: TM-T3068
1mg47.00€2mg60.00€5mg95.00€10mg170.00€25mg299.00€50mg499.00€100mg723.00€1mL*10mM (DMSO)97.00€
